Wacker Biosolutions to focus on biotechnology
Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology
Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.
The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.
Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.
"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.
Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.
You may also like
Trending Articles
Upcoming event
You may also like
Manufacturing
Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks
Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and
other highly regulated industries
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines
Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Manufacturing
AQUARIA - enhancing drying performance while reducing consumption
AQUARIA stands out within the diverse range of parts washers for the pharmaceutical industry that have been developed by IMA over the last two decades. Designed to ensure maximum performance in cleaning and validation with high efficiency, AQUARIA is renowned for its reduced consumption of energy, water, detergents and compressed air. These qualities match the pharmaceutical industry’s current attention to environmental issues and prove how IMA is actively supporting sustainability across a wide spectrum of processes, where its solutions represent a respected benchmark